Equities

USANA Health Sciences Inc

USANA Health Sciences Inc

Actions
Consumer Staples Food Producers
  • Price (USD)38.10
  • Today's Change-0.32 / -0.83%
  • Shares traded18.21k
  • 1 Year change-35.93%
  • Beta0.8998
Data delayed at least 15 minutes, as of Sep 16 2024 18:22 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy0
Outperform0
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 2 analysts offering 12 month price targets for USANA Health Sciences, Inc. have a median target of 48.00, with a high estimate of 58.00 and a low estimate of 38.00. The median estimate represents a 24.93% increase from the last price of 38.42.
High51.0%58.00
Med24.9%48.00
Low-1.1%38.00

Earnings history & estimates in USD

On Jul 23, 2024, USANA Health Sciences, Inc. reported 2nd quarter 2024 earnings of 0.540 per share.
The next earnings announcement is expected on Oct 22, 2024.
Average growth rate-6.15%
USANA Health Sciences, Inc. reported annual 2023 earnings of 3.30 per share on Feb 06, 2024.
Average growth rate-3.69%
More ▼

Revenue history & estimates in USD

USANA Health Sciences, Inc. had 2nd quarter 2024 revenues of 212.87m. This missed the 220.99m consensus estimate of the 2 analysts following the company. This was 14.29% below the prior year's 2nd quarter results.
Average growth rate-2.58%
USANA Health Sciences, Inc. had revenues for the full year 2023 of 921.01m. This was 7.77% below the prior year's results.
Average growth rate-3.02%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.